Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Study data from Fox Chase Cancer Center, Department of Medical Oncology update knowledge of cancer gene therapy
April 21st, 2009
Scientists discuss in 'The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis' new findings in cancer gene therapy. "Birt-Hogg-Dubé (BHD) syndrome is a tumor-suppressor gene disorder characterized by skin tumors, cystic lung disease and renal cell carcinoma. Very little is known about the molecular pathogenesis of BHD," scientists in the United States report. "Clinical similarities between BHD and tuberous sclerosis complex (TSC) suggest that the BHD and TSC proteins may function within a common pathway. The TSC proteins inhibit the activity of the mammalian target of rapamycin complex 1 (TORC1), and in Schizosaccharomyces pombe, Bhd and...
Source: Cancer Weekly (2009-04-21)
|
